BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1778 related articles for article (PubMed ID: 18278195)

  • 1. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
    Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
    Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
    J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
    Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
    Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent.
    Schaden E; Schober A; Hacker S; Spiss C; Chiari A; Kozek-Langenecker S
    Blood Coagul Fibrinolysis; 2010 Apr; 21(3):256-61. PubMed ID: 20087172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement.
    Virtanen L; Salmela B; Leinonen J; Lemponen M; Huhtala J; Joutsi-Korhonen L; Lassila R
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):597-603. PubMed ID: 24732174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
    Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications.
    Harder S; Parisius J; Picard-Willems B
    Thromb Res; 2008; 123(2):396-403. PubMed ID: 18571698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
    Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
    Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kaolin-based activated coagulation time measured by sonoclot in patients undergoing cardiopulmonary bypass.
    Ganter MT; Monn A; Tavakoli R; Klaghofer R; Zollinger A; Hofer CK
    J Cardiothorac Vasc Anesth; 2007 Aug; 21(4):524-8. PubMed ID: 17678778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
    Hellstern P; Bach J; Simon M; Saggau W
    J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
    Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
    Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 89.